3/26
08:01 am
smmt
Summit Therapeutics Inc. (NASDAQ: SMMT) was upgraded by analysts at Citigroup Inc. from a "neutral" rating to a "buy" rating. They now have a $35.00 price target on the stock, up previously from $23.00.
Medium
Report
Summit Therapeutics Inc. (NASDAQ: SMMT) was upgraded by analysts at Citigroup Inc. from a "neutral" rating to a "buy" rating. They now have a $35.00 price target on the stock, up previously from $23.00.
3/26
07:50 am
smmt
Rating for SMMT
Medium
Report
Rating for SMMT
3/26
07:50 am
smmt
Rating for SMMT
Medium
Report
Rating for SMMT
3/26
05:06 am
smmt
Summit Therapeutics upgraded to Buy from Neutral at Citi
Medium
Report
Summit Therapeutics upgraded to Buy from Neutral at Citi
3/21
10:12 am
smmt
Rating for SMMT
Low
Report
Rating for SMMT
3/21
08:15 am
smmt
Summit Therapeutics Inc. (NASDAQ: SMMT) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating on the stock.
Low
Report
Summit Therapeutics Inc. (NASDAQ: SMMT) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating on the stock.
3/21
08:15 am
smmt
Summit Therapeutics Inc. (NASDAQ: SMMT) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating on the stock.
Low
Report
Summit Therapeutics Inc. (NASDAQ: SMMT) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating on the stock.
3/21
08:07 am
smmt
Summit Therapeutics initiated with an Overweight at Cantor Fitzgerald
Report
Summit Therapeutics initiated with an Overweight at Cantor Fitzgerald
3/21
05:57 am
smmt
Summit Therapeutics initiated with an Overweight at Cantor Fitzgerald
Low
Report
Summit Therapeutics initiated with an Overweight at Cantor Fitzgerald
3/12
07:38 am
smmt
Summit Therapeutics Inc. (NASDAQ: SMMT) is now covered by analysts at Evercore ISI. They set an "outperform" rating and a $30.00 price target on the stock.
Medium
Report
Summit Therapeutics Inc. (NASDAQ: SMMT) is now covered by analysts at Evercore ISI. They set an "outperform" rating and a $30.00 price target on the stock.
3/12
07:38 am
smmt
Summit Therapeutics Inc. (NASDAQ: SMMT) is now covered by analysts at Evercore ISI. They set an "outperform" rating and a $30.00 price target on the stock.
Medium
Report
Summit Therapeutics Inc. (NASDAQ: SMMT) is now covered by analysts at Evercore ISI. They set an "outperform" rating and a $30.00 price target on the stock.
3/12
07:29 am
smmt
Rating for SMMT
Medium
Report
Rating for SMMT
3/12
06:35 am
smmt
Summit Therapeutics initiated with an Outperform at Evercore ISI
Medium
Report
Summit Therapeutics initiated with an Outperform at Evercore ISI
3/12
06:35 am
smmt
Summit Therapeutics initiated with an Outperform at Evercore ISI
Medium
Report
Summit Therapeutics initiated with an Outperform at Evercore ISI
2/28
08:03 am
smmt
Rating for SMMT
Medium
Report
Rating for SMMT
2/28
08:03 am
smmt
Rating for SMMT
Medium
Report
Rating for SMMT
2/28
08:03 am
smmt
Rating for SMMT
Medium
Report
Rating for SMMT
2/28
06:14 am
smmt
Summit Therapeutics initiated with a Buy at Goldman Sachs
High
Report
Summit Therapeutics initiated with a Buy at Goldman Sachs
2/28
06:14 am
smmt
Summit Therapeutics initiated with a Buy at Goldman Sachs
High
Report
Summit Therapeutics initiated with a Buy at Goldman Sachs
2/28
06:14 am
smmt
Summit Therapeutics initiated with a Buy at Goldman Sachs
High
Report
Summit Therapeutics initiated with a Buy at Goldman Sachs
2/25
08:00 am
smmt
Summit Therapeutics Inc. (NASDAQ: SMMT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $44.00 price target on the stock.
Medium
Report
Summit Therapeutics Inc. (NASDAQ: SMMT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $44.00 price target on the stock.
1/21
08:02 am
smmt
Summit Therapeutics Inc. (NASDAQ: SMMT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $44.00 price target on the stock.
High
Report
Summit Therapeutics Inc. (NASDAQ: SMMT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $44.00 price target on the stock.